Biogen Inc

18 de set. de 2026, 20:02 UTC

Biogen Inc shares fell sharply, reversing a trend of higher daily closes observed in recent sessions and breaking from upward momentum since Thursday's close.

17 de set. de 2026, 20:07 UTC

Biogen Inc. shares advanced after Japan approved its subcutaneous formulation of LEQEMBI®, enhancing its Alzheimer's treatment portfolio in today's trading.

16 de set. de 2026, 20:21 UTC

Biogen Inc's LEQEMBI® receives approval in Japan for a new administration route, while the stock is modestly lower in after-market trading.

15 de set. de 2026, 20:07 UTC

Biogen Inc shares are lower today, influenced by a drop in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

14 de set. de 2026, 20:08 UTC

Biogen Inc. shares are advancing, supported by strong performances from key holdings in the health care sector. The broader market reflects modest gains.

11 de set. de 2026, 20:08 UTC

Biogen Inc is rising after Needham named it a top biotechnology pick, maintaining a Buy rating amid expectations for future growth and clinical developments.

10 de set. de 2026, 20:07 UTC

Stifel reiterated a Buy rating on Biogen and raised its price target to $242, while HSBC maintained a Reduce rating with a target increase to $175.

9 de set. de 2026, 20:07 UTC

Biogen Inc shares are lower in Wednesday's session, with no specific news identified. The broader market decline may be influencing the asset's performance.

8 de set. de 2026, 23:06 UTC

Biogen Inc shares are modestly higher in after-market trading, continuing positive sentiment since Tuesday's close. Broader market conditions reflect strong U.S. labor data.

4 de set. de 2026, 23:46 UTC

Biogen Inc shares are lower in after-market hours, with no specific news driving the decline. Broader economic signals are contributing to market uncertainty.

3 de set. de 2026, 19:16 UTC

Biogen and Eisai received approval for LEQEMBI in China for early Alzheimer's treatment. Piper Sandler raised Biogen's price target to $245, maintaining an Overweight rating.

2 de set. de 2026, 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

1 de set. de 2026, 21:01 UTC

Biogen Inc. shares are lower in after-market hours, continuing a downward trend over the past three sessions with no specific news identified.

31 de ago. de 2026, 19:46 UTC

Biogen Inc's shares are lower amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh at the Jackson Hole symposium.

28 de ago. de 2026, 21:01 UTC

Biogen Inc shares are lower in after-market hours, reflecting broader market weakness. No specific news was identified to explain the decline.

26 de ago. de 2026, 20:08 UTC

Biogen Inc. has chosen Veeva Systems' Veeva Vault CRM to enhance its digital strategy, with shares rising during Wednesday's session amid positive sentiment.

25 de ago. de 2026, 23:26 UTC

Biogen Inc. shares are trading roughly flat in after-market hours. Crude oil prices have declined, easing some geopolitical tensions, impacting overall market sentiment.

24 de ago. de 2026, 20:13 UTC

Biogen Inc shares are trading lower in after-market hours. Broader market conditions may be influencing trading sentiment amid U.S.-Iran tensions and inflation concerns.

21 de ago. de 2026, 20:06 UTC

Biogen Inc is trading higher since Thursday's close, reflecting positive market trends. The stock remains above its 20-day moving average despite a recent pullback.

20 de ago. de 2026, 20:01 UTC

Shares lower today amid broader market declines and ETF drop.

19 de ago. de 2026, 23:06 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Wednesday's close. The asset remains above its 20-day moving average.

17 de ago. de 2026, 19:46 UTC

Biogen Inc. shares are lower today amid routine trading, despite an unexpected rise in the New York manufacturing index supporting broader market conditions.

14 de ago. de 2026, 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting routine fluctuations. The stock remains above its 20-day moving average and near its monthly range high.

13 de ago. de 2026, 20:06 UTC

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12 de ago. de 2026, 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11 de ago. de 2026, 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

10 de ago. de 2026, 19:36 UTC

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

7 de ago. de 2026, 23:16 UTC

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

6 de ago. de 2026, 23:11 UTC

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

5 de ago. de 2026, 19:26 UTC

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.